VIR
Vir Biotechnology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About VIR
Vir Biotechnology, Inc.
A biotech company developing innovative treatments for infectious diseases, including hepatitis B and COVID-19
1800 Owens Street, Suite 900, San Francisco, California 94158
--
Vir Biotechnology, Inc., was incorporated under the laws of the State of Delaware on April 7, 2016. The company is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious diseases, including virus-related diseases. The company aims to achieve this in two basic ways — first, by developing powerful antibody therapies, and second, by generating unique T-cell responses in vivo through a T-cell-based viral vector platform.
Company Financials
EPS
VIR has released its 2024 Q4 earnings. EPS was reported at -0.76, versus the expected -0.87, beating expectations. The chart below visualizes how VIR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VIR has released its 2024 Q4 earnings report, with revenue of 12.37M, reflecting a YoY change of -26.29%, and net profit of -104.59M, showing a YoY change of 9.82%. The Sankey diagram below clearly presents VIR’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
